Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Madjid Djouina is active.

Publication


Featured researches published by Madjid Djouina.


Bioorganic & Medicinal Chemistry | 2013

3-Carboxamido-5-aryl-isoxazoles as new CB2 agonists for the treatment of colitis.

Aurélien Tourteau; Virginie Andrzejak; Mathilde Body-Malapel; Lucas Lemaire; Amélie Lemoine; Roxane Mansouri; Madjid Djouina; Nicolas Renault; Jamal El Bakali; Pierre Desreumaux; Giulio G. Muccioli; Didier M. Lambert; Philippe Chavatte; Benoît Rigo; Natascha Leleu-Chavain; Régis Millet

Recent investigations showed that anandamide, the main endogenous ligand of CB1 and CB2 cannabinoid receptors, possesses analgesic, antidepressant and anti-inflammatory effects. In the perspective to treat inflammatory bowel disease (IBD), our approach was to develop new selective CB2 receptor agonists without psychotropic side effects associated to CB1 receptors. In this purpose, a new series of 3-carboxamido-5-aryl-isoxazoles, never described previously as CB2 receptor agonists, was designed, synthesized and evaluated for their biological activity. The pharmacological results have identified great selective CB2 agonists with in vivo anti-inflammatory activity in a DSS-induced acute colitis mouse model.


Bioorganic & Medicinal Chemistry | 2011

New FAAH inhibitors based on 3-carboxamido-5-aryl-isoxazole scaffold that protect against experimental colitis

Virginie Andrzejak; Giulio G. Muccioli; Mathilde Body-Malapel; Jamal El Bakali; Madjid Djouina; Nicolas Renault; Philippe Chavatte; Pierre Desreumaux; Didier M. Lambert; Régis Millet

Growing evidence suggests a role for the endocannabinoid (EC) system, in intestinal inflammation and compounds inhibiting anandamide degradation offer a promising therapeutic option for the treatment of inflammatory bowel diseases. In this paper, we report the first series of carboxamides derivatives possessing FAAH inhibitory activities. Among them, compound 39 displayed significant inhibitory FAAH activity (IC(50)=0.088 μM) and reduced colitis induced by intrarectal administration of TNBS.


Journal of Medicinal Chemistry | 2010

4-Oxo-1,4-dihydropyridines as Selective CB2 Cannabinoid Receptor Ligands: Structural Insights into the Design of a Novel Inverse Agonist Series

Jamal El Bakali; Giulio G. Muccioli; Nicolas Renault; Delphine Pradal; Mathilde Body-Malapel; Madjid Djouina; Laurie Hamtiaux; Virginie Andrzejak; Pierre Desreumaux; Philippe Chavatte; Didier M. Lambert; Régis Millet

Growing evidence shows that CB(2) receptor is an attractive therapeutic target. Starting from a series of 4-oxo-1,4-dihydroquinoline-3-carboxamide as selective CB(2) agonists, we describe here the medicinal chemistry approach leading to the development of CB(2) receptor inverse agonists with a 4-oxo-1,4-dihydropyridine scaffold. The compounds reported here show high affinity and potency at the CB(2) receptor while showing only modest affinity for the centrally expressed CB(1) cannabinoid receptor. Further, we found that the functionality of this series is controlled by its C-6 substituent because agonists bear a methyl or a tert-butyl group and inverse agonists, a phenyl or 4-chlorophenyl group, respectively. Finally, in silico studies suggest that the C-6 substituent could modulate the conformation of W6.48 known to be critical in GPCR activation.


Journal of Medicinal Chemistry | 2012

4-Oxo-1,4-dihydropyridines as selective CB₂ cannabinoid receptor ligands. Part 2: discovery of new agonists endowed with protective effect against experimental colitis

Jamal El Bakali; Pauline Gilleron; Mathilde Body-Malapel; Roxane Mansouri; Giulio G. Muccioli; Madjid Djouina; Amélie Barczyk; Frédérique Klupsch; Virginie Andrzejak; Emmanuelle Lipka; Christophe Furman; Didier M. Lambert; Philippe Chavatte; Pierre Desreumaux; Régis Millet

Further on to our earlier work on the 4-oxo-1,4-dihydropyridine, we describe herein our strategy to get access to potent selective CB₂ receptor agonists. Thus, we designed and synthesized 29 compounds, evaluated on both hCB₁ and hCB₂ cannabinoid receptors, and assessed 11 of them in the TNBS-induced colitis model in mice. Compound 48 was found to be the most efficient of our series, exhibiting an exquisite protection against experimental colitis, superior to the one observed after treatment with Pentasa.


Food and Chemical Toxicology | 2016

Toxicological consequences of experimental exposure to aluminum in human intestinal epithelial cells.

Madjid Djouina; N. Esquerre; Pierre Desreumaux; Cécile Vignal; Mathilde Body-Malapel

Aluminum (Al), a non-essential element, is ubiquitous in industrialized societies. Whereas adult intake is estimated between 3 and 12 mg/day according to dietary aluminum studies conducted in many countries, it is not known if aluminum may have a toxic effect on intestinal epithelium. The aim of this work was to evaluate the cytotoxicity and RNA expression patterns induced in HT-29 cells by aluminum. Both classical toxicological methods and a global transcriptomic approach were used. Cytotoxicity determined by MTT assay showed a time and dose dependent decrease of cell viability in aluminum treated cells compared to control cells. Cell cycle analysis by flow cytometry revealed that aluminum induced accumulation of cells in phase G0/G1, associated with a decrease in the proportion of cells in S and G2/M phases. Aluminum led to apoptosis as evidenced by nuclear morphology changes and mitochondrial membrane perturbations, and induced reactive oxygen species generation. Transcriptomic pattern argued in favor of pro-tumorigenic and pro-inflammatory effects of aluminum in intestinal epithelial cells. These results highlight several pathways by which aluminum has a disturbing impact on intestinal epithelial cells, supporting that the effects of aluminum on intestine warrants further investigation.


ACS Medicinal Chemistry Letters | 2015

Conformational Restriction Leading to a Selective CB2 Cannabinoid Receptor Agonist Orally Active Against Colitis

Jamal El Bakali; Giulio G. Muccioli; Mathilde Body-Malapel; Madjid Djouina; Frédérique Klupsch; Alina Ghinet; Amélie Barczyk; Nicolas Renault; Philippe Chavatte; Pierre Desreumaux; Didier M. Lambert; Régis Millet

The CB2 cannabinoid receptor has been implicated in the regulation of intestinal inflammation. Following on from the promising activity of a series of 4-oxo-1,4-dihydroquinoline-3-carboxamide, we developed constrained analogues based on a 2H-pyrazolo[4,3-c]quinolin-3(5H)-one scaffold, with improved affinity for the hCB2 receptor and had very high selectivity over the hCB1 receptor. Importantly, the lead of this series (26, hCB2: K i = 0.39 nM, hCB1: K i > 3000 nM) was found to protect mice against experimental colitis after oral administration.


Bioorganic & Medicinal Chemistry Letters | 2014

Switching cannabinoid response from CB2 agonists to FAAH inhibitors

Aurélien Tourteau; Natascha Leleu-Chavain; Mathilde Body-Malapel; Virginie Andrzejak; Amélie Barczyk; Madjid Djouina; Benoît Rigo; Pierre Desreumaux; Philippe Chavatte; Régis Millet

A series of 3-carboxamido-5-aryl-isoxazoles designed as CB2 agonists were evaluated as FAAH inhibitors. The pharmacological results led to identify structure-activity relationships enabling to switch cannabinoid response from CB2 agonists to FAAH inhibitors. Two compounds were selected for their FAAH and/or CB2 activity, and evaluated in a colitis model for their anti-inflammatory activity. Results showed that compounds 10 and 11 inhibit the development of DSS-induced acute colitis in mice and then, are interesting leads to explore new drug candidates for IBD.


Cellular and molecular gastroenterology and hepatology | 2018

Aluminum Ingestion Promotes Colorectal Hypersensitivity in Rodents

Nicolas Esquerre; Lilian Basso; Caroline Dubuquoy; Madjid Djouina; Daniel Chappard; Catherine Blanpied; Pierre Desreumaux; Nathalie Vergnolle; Cécile Vignal; Mathilde Body-Malapel

Background & Aims Irritable bowel syndrome (IBS) is a multifactorial disease arising from a complex interplay between genetic predisposition and environmental influences. To date, environmental triggers are not well known. Aluminum is commonly present in food, notably by its use as food additive. We investigated the effects of aluminum ingestion in rodent models of visceral hypersensitivity, and the mechanisms involved. Methods Visceral hypersensitivity was recorded by colorectal distension in rats administered with oral low doses of aluminum. Inflammation was analyzed in the colon of aluminum-treated rats by quantitative PCR for cytokine expression and by immunohistochemistry for immune cells quantification. Involvement of mast cells in the aluminum-induced hypersensitivity was determined by cromoglycate administration of rats and in mast cell-deficient mice (KitW-sh/W-sh). Proteinase-activated receptor-2 (PAR2) activation in response to aluminum was evaluated and its implication in aluminum-induced hypersensitivity was assessed in PAR2 knockout mice. Results Orally administered low-dose aluminum induced visceral hypersensitivity in rats and mice. Visceral pain induced by aluminum persisted over time even after cessation of treatment, reappeared and was amplified when treatment resumed. As observed in humans, female animals were more sensitive than males. Major mediators of nociception were up-regulated in the colon by aluminum. Activation of mast cells and PAR2 were required for aluminum-induced hypersensitivity. Conclusions These findings indicate that oral exposure to aluminum at human dietary level reproduces clinical and molecular features of IBS, highlighting a new pathway of prevention and treatment of visceral pain in some susceptible patients.


Particle and Fibre Toxicology | 2017

Effects of urban coarse particles inhalation on oxidative and inflammatory parameters in the mouse lung and colon

Cécile Vignal; Muriel Pichavant; Laurent Y. Alleman; Madjid Djouina; Florian Dingreville; Esperanza Perdrix; Christophe Waxin; Adil Ouali Alami; Corinne Gower-Rousseau; Pierre Desreumaux; Mathilde Body-Malapel


Gastroenterology | 2018

1053 - Hla B27 Transgenic Rat: A New Animal Model of Ileitis Post Surgery Reproducing Inflammatory Disease

Amélie Chau; Lucil Schneider; Charbel Chater; Silvia Speca; Madjid Djouina; Caroline Dubuquoy; Dine Koriche; Laurent Dubuquoy; Christel Neut; François-René Pruvot; Pierre Desreumaux; Philippe Zerbib; Benjamin Pariente

Collaboration


Dive into the Madjid Djouina's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Didier M. Lambert

Université catholique de Louvain

View shared research outputs
Top Co-Authors

Avatar

Giulio G. Muccioli

Université catholique de Louvain

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge